Edition:
United Kingdom

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

3.00USD
23 Aug 2019
Change (% chg)

$-0.13 (-4.15%)
Prev Close
$3.13
Open
$3.10
Day's High
$3.21
Day's Low
$2.98
Volume
54,220
Avg. Vol
64,526
52-wk High
$32.25
52-wk Low
$2.88

Latest Key Developments (Source: Significant Developments)

Aptinyx Inc - QTRLY Loss Per Share $0.36
Monday, 12 Aug 2019 

Aptinyx Inc ::APTINYX REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS.APTINYX INC - QTRLY LOSS PER SHARE $0.36.APTINYX INC - CASH AND CASH EQUIVALENTS WERE $124.9 MILLION AT JUNE 30, 2019 COMPARED TO $150.6 MILLION AT DECEMBER 31, 2018..APTINYX INC - QTRLY REVENUE $925,000 VERSUS $2.1 MILLION.  Full Article

Aptinyx Says Entered Into Sales Agreement With Cowen And Co
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Aptinyx Inc ::APTINYX INC - ENTERED INTO SALES AGREEMENT WITH COWEN AND COMPANY, LLC RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS.APTINYX INC - MAY OFFER, SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $50.0 MILLION FROM TIME TO TIME.APTINYX INC - THIS PROSPECTUS IS OFFERING OF UP TO AGGREGATE OF $24.0 MILLION IN SHARES OF COMMON STOCK.APTINYX INC - WILL BE REQUIRED TO FILE ANOTHER PROSPECTUS IN EVENT CO WANT TO OFFER MORE THAN $24.0 MILLION IN SHARES OF COMMON STOCK.  Full Article

Aptinyx Reports Positive Top-Line Data From Mid-Stage Study In Patients With Fibromyalgia
Monday, 10 Jun 2019 

June 10 (Reuters) - Aptinyx Inc ::APTINYX REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2 STUDY OF NYX-2925 IN PATIENTS WITH FIBROMYALGIA, DEMONSTRATING SIGNIFICANT EFFECTS ON BOTH BIOMARKERS AND PATIENT-REPORTED PAIN.APTINYX INC - NYX-2925 WAS WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED.APTINYX INC - NYX-2925 DEMONSTRATED STATISTICALLY SIGNIFICANT EFFECTS ON A RANGE OF NEUROIMAGING BIOMARKERS AND PATIENT-REPORTED OUTCOMES.APTINYX INC - NEUROIMAGING BIOMARKERS CORRELATED WITH PATIENT-REPORTED PAIN IMPROVEMENTS.APTINYX INC - STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS WERE ALSO OBSERVED ON SECONDARY PATIENT-REPORTED ENDPOINTS.APTINYX INC - WILL BEGIN ENROLLMENT IN A LARGER, 12-WEEK, STUDY IN PATIENTS WITH FIBROMYALGIA IN SECOND HALF OF 2019.  Full Article

Data In Parkinson's Disease Model In Non-Human Primates Demonstrate Reversal Of Cognitive Deficits With Novel Nmda Receptor Modulator, Nyx-458
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Aptinyx Inc ::DATA IN PARKINSON'S DISEASE MODEL IN NON-HUMAN PRIMATES DEMONSTRATE REVERSAL OF COGNITIVE DEFICITS WITH NOVEL NMDA RECEPTOR MODULATOR, NYX-458.APTINYX INC - ADMINISTRATION OF NYX-458 RESULTED IN RAPID, ROBUST, AND LONG-LASTING IMPROVEMENTS IN COGNITIVE PERFORMANCE ACROSS BATTERY OF TESTS.APTINYX INC - APTINYX PLANS TO INITIATE A PHASE 2 STUDY IN PEOPLE WITH PARKINSON'S DISEASE IN SECOND HALF OF 2019..APTINYX INC - EXPECTS TO REPORT DATA FROM PHASE 1 NYX-458 STUDY IN FIRST HALF OF 2019..  Full Article

Aptinyx Reports Top-Line Results From Phase 2 Clinical Study Of NYX-2925
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Aptinyx Inc ::EXPECTS TO ANNOUNCE DATA FROM FULL ANALYSIS OF PHASE 2 STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA IN H1 2019 .APTINYX REPORTS TOP-LINE RESULTS FROM PHASE 2 CLINICAL STUDY OF NYX-2925 IN PAINFUL DIABETIC PERIPHERAL NEUROPATHY.NYX-2925 WAS WELL-TOLERATED WITH NO SIGNIFICANT ADVERSE EVENTS.NYX-2925 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO ON PRIMARY ENDPOINT.NYX-2925 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO ON PRIMARY ENDPOINT.OF THREE DOSE LEVELS EVALUATED, 50 MG SHOWED MOST MEANINGFUL IMPROVEMENTS ACROSS MULTIPLE MEASURES.  Full Article

Aptinyx Reports Positive Data From Interim Analysis Of Exploratory Study Of NYX-2925 In Subjects With Fibromyalgia
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Aptinyx Inc ::APTINYX REPORTS POSITIVE DATA FROM INTERIM ANALYSIS OF EXPLORATORY STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA.APTINYX INC - OBSERVED CORRESPONDING TRENDS OF IMPROVEMENT ON MULTIPLE SECONDARY ENDPOINTS.APTINYX INC - NYX-2925 WAS WELL TOLERATED WITH NO SUBJECTS REPORTING TREATMENT-RELATED SERIOUS ADVERSE EVENTS.APTINYX INC - NYX-2925 STUDY IS ONGOING WITH FULL DATA EXPECTED TO READ OUT IN FIRST HALF OF 2019.APTINYX INC - EXPECTS TO INITIATE A LARGER PHASE 2 STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA IN 2019.APTINYX INC - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY IMAGING-BASED ENDPOINT, CHANGES IN MARKERS OF CENTRAL PAIN PROCESSING, IN 11 SUBJECTS.  Full Article

Aptinyx Q3 Loss Per Share $0.43
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aptinyx Inc ::APTINYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-1.01 -- THOMSON REUTERS I/B/E/S.PLANS TO ANNOUNCE DATA FROM INTERIM ANALYSIS OF EXPLORATORY FIBROMYALGIA STUDY IN DECEMBER 2018.  Full Article

Aptinyx Completes Enrollment In Phase 2 Study Of Nyx-2925 For Painful Diabetic Peripheral Neuropathy
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aptinyx Inc ::APTINYX COMPLETES ENROLLMENT IN PHASE 2 STUDY OF NYX-2925 FOR PAINFUL DIABETIC PERIPHERAL NEUROPATHY.APTINYX INC - TOP-LINE DATA EXPECTED EARLY IN Q1 OF 2019.APTINYX INC - STUDY IS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.  Full Article

Frazier Life Sciences VIII LP Reports 9.5 Pct Stake In Aptinyx Inc
Thursday, 5 Jul 2018 

July 5 (Reuters) - Aptinyx Inc ::FRAZIER LIFE SCIENCES VIII LP SAYS REPORTS 9.5 PERCENT STAKE IN APTINYX INC AS OF JUNE 25 - SEC FILING.FRAZIER LIFE SCIENCES VIII LP SAYS ACQUIRED APTINYX INC SHARES FOR INVESTMENT PURPOSES.  Full Article

Bain Capital Life Sciences Fund LP Reports A 6.2 Pct Stake In Aptinyx As Of June 25
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Aptinyx Inc ::BAIN CAPITAL LIFE SCIENCES FUND LP REPORTS A 6.2 PCT STAKE IN APTINYX AS OF JUNE 25 - SEC FILING.  Full Article